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Purpose: An overview of the Rapid Learning methodology, its results, and the potential impact on radio-
therapy.
Material and results: Rapid Learning methodology is divided into four phases. In the data phase, diverse
data are collected about past patients, treatments used, and outcomes. Innovative information technol-
ogies that support semantic interoperability enable distributed learning and data sharing without addi-
tional burden on health care professionals and without the need for data to leave the hospital. In the
knowledge phase, prediction models are developed for new data and treatment outcomes by applying
machine learning methods to data. In the application phase, this knowledge is applied in clinical practice
via novel decision support systems or via extensions of existing models such as Tumour Control Proba-
bility models. In the evaluation phase, the predictability of treatment outcomes allows the new knowl-
edge to be evaluated by comparing predicted and actual outcomes.
Conclusion: Personalised or tailored cancer therapy ensures not only that patients receive an optimal
treatment, but also that the right resources are being used for the right patients. Rapid Learning
approaches combined with evidence based medicine are expected to improve the predictability of out-
come and radiotherapy is the ideal ﬁeld to study the value of Rapid Learning. The next step will be to
include patient preferences in the decision making.
 2013 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy
and Oncology 109 (2013) 159–164
Open access under CC BY-NC-ND license.Tailored cancer therapies, in which speciﬁc information about
patients and tumours is taken into account during treatment deci-
sions, are an important step forward from current population-
based therapy [1] However, given the developments outlined be-
low, it is becoming increasingly difﬁcult to identify the best treat-
ment for an individual cancer patient:
 Tumours and patients seem to be even less homogeneous than
previously assumed, meaning the same treatments can have
different outcomes in patients who have the same type of
tumour. For instance, there are at least four molecular subtypesof breast cancer, each with very different outcomes [2]. Based
on gene signatures various subgroups of tumours can be identi-
ﬁed [3–8].
 The number of treatment options is increasing. For example,
early stage prostate cancer can now be treated with conserva-
tive treatment, prostatectomy, external radiotherapy, stereotac-
tic radiotherapy, LDR or HDR brachytherapy, high-intensity
focused ultrasound, hormone therapy, combination therapies
and so on. A different example is the recent rise of targeted
therapies that are rapidly growing in numbers. Performing clas-
sic randomised trials to compare all new treatment options
with the ‘‘gold standard’’ is becoming impossible by the current
speed of innovation.
 The evidence for the right choice in an individual patient is
inadequate. First, ‘evidence-based medicine’ and the ensuing
guidelines always lag somewhat behind practice, particularly
in highly technological, innovative and rapidly evolving ﬁelds
such as radiotherapy. In addition, translating the results of clin-
ical trials to the general patient population and environment is
Fig. 2. Four phases of Rapid Learning [13].
160 Rapid Learning healthcare in oncologynot straightforward, given the higher quality of care in clinical
trials and the known selection bias (trials reach no more than
3% of cancer patients, in radiotherapy this ﬁgure is even lower)
[9–11]. Finally, given the developments mentioned above –
more treatment options and less homogeneous patient groups
– the urgency to scaffold our treatment decisions with robust
knowledge and the demand for evidence-based medicine is lar-
ger than ever.
 It is becoming more difﬁcult to ﬁnd the right evidence. Despite
– or perhaps due to – the fact that papers are being published in
rapidly increasing numbers (e.g., as a radiation-oncologist spe-
cialising in lung cancer, has to read around eight articles per
day to keep up with the literature [12]), it is difﬁcult to match
the characteristics of the individual patient to evidence from
the literature and to evaluate the quality of that evidence.
The developments illustrated above have given rise to a search
for an alternative to the elaborate consensus- and evidence-based
guideline medicine format when it comes to making treatment
decisions. The alternative discussed in this article is rapid learning
[13]. Although it is known under various names, including Knowl-
edge-driven Healthcare, Computer Assisted Theragnostics and
Learning Intelligence Network, the basic idea in all cases is the (re)-
use of historical data from routine clinical practice for decisions
concerning new patients or to test new hypothesis [14–19]
(Fig. 1). This has a number of obvious advantages, such as the large
number of readily available patients and less selection bias com-
pared to clinical trials. However, it also has some important disad-
vantages; for example, the quality of the data in clinical practice is
much lower than in clinical trials [20]. There is a long very success-
ful history of putting genomic data public and reusing them [3–8].
This paper provides an overview of the methods used in Rapid
Learning, the initial results, and an outlook as to how the tech-
niques involved may inﬂuence clinical radiotherapy.Methods and results
Rapid Learning involves four phases (Fig. 2) [13] which are con-
tinually iterated. In the data phase, data on past patients are col-
lected, including their delivered treatments and outcomes. In the
knowledge phase, knowledge is generated from these data. In the
application phase, this knowledge is applied to clinical practice.
In the ﬁnal evaluation phase, the outcomes are evaluated, after
which the ﬁrst phase starts again. In every phase, external knowl-Fig. 1. Current paradigm versus future paradigm (modiﬁed from [43]).edge (e.g., from clinical trials) is used to optimise the phase. The
sections below describe the methods used and examples of typical
results for every phase.Data
Rapid Learning requires both a great deal of data and a large
diversity of data. The amount of data is important (a) to obtain
higher quality knowledge (the quality of the knowledge correlates
with the number of patients on which that knowledge is based)
and (b) to be able to generate knowledge concerning smaller, more
homogeneous patient groups and/or use more variables in the
knowledge phase. The diversity of the data (particularly with re-
spect to the treatments used, but also in terms of patient character-
istics) is important to ultimately decide which treatment is best for
an individual patient.
Obtaining enough data of sufﬁcient quality and diversity is the
biggest challenge in Rapid Learning. This is only possible if data are
shared across institutional and national borders, both academic
and community health care systems. Such data sharing is ham-
pered by a lack of time; differences in language and culture as well
as data recording practices; the academic and political value of
data; risks to reputation; privacy and legal aspects and so on.
Nonetheless, one project that has made successful use of data shar-
ing is euroCAT (www.eurocat.info), a collaborative project involv-
ing radiotherapy institutes in the Netherlands, Germany and
Belgium. A crucial factor in the success of this project was the
use of innovative information technologies, which made it possible
to learn from each other’s data without the data having to leave the
institution (a concept known as distributed learning). Another
important factor was the development of a dataset with semantic
interoperability (also known as ‘data with linguistic unity’ or ‘ma-
chine-readable data’), in which local terms are converted into con-
cepts from a well-deﬁned ontology (e.g., NCI Thesaurus, SNOMED).
In such an approach, the ontology terms serve as a common inter-
face to the data at each institutional site, enabling a common ap-
proach to information retrieval and reasoning facilitated through
a semantic portal to the data. This semantic interoperability ap-
proach also allows one to add data from clinical trials to further
strengthen the data available to Rapid Learning.
The data collected in routine clinical care are often of lower
quality compared to data from clinical trials. Data captured in rou-
tine care are often incorrect, contradictory, missing and biased.
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data, it is important to include data quality improvement protocols
varying from simple logic (e.g. it is impossible to be 60 kg and have
a BMI of 32) to more probabilistic approaches (e.g. for a similar pa-
tient cohort the median value of the maximal standard uptake va-
lue from 18-FDG PET scans should be similar between two
institutes). A positive effect of such initiatives is that they give rise
to increasing coordination with respect to what data need to be
collected and how (i.e., disease-speciﬁc ‘umbrella’ protocols). The
end users of the knowledge, the provider and the patient, not only
need to gain insight into effects of various treatment options, but
also in uncertainties, conﬂicting data, and toxicities and other
treatment burden.
It should be noted that getting data in the proposed manner
does not mean that there is a need to capture more data, which
would be an unacceptable additional burden to often overloaded
professionals. Rather, the data that are already captured in routine
care and in clinical trials are combined and re-used. There are var-
ious prototypes to do this such as in the euroCAT project where a
fully automated, daily synchronisation of the clinical databases
into a semantically interoperable dataset takes place.Knowledge
Machine learning is used to extract knowledge from great
amounts of data. In machine learning, models/algorithms are
developed that best describe the data but that can also make pre-
dictions for new, unseen data. Models trained on retrospective data
may be used to predict the outcomes (e.g., survival, quality of life,
toxicity, etc.) of various treatments on the basis of data from a new
patient. Obviously, it is crucial that such models are adequately
validated [21]; an unvalidated model is of very limited value. To
this end, a validation set should always be available, preferably
from a different institute than that from which the data were used
to create the model. Examples of radiotherapy models (on the basis
of both clinical trials and Rapid Learning) are available for non-
small cell lung, rectal and head-and-neck cancer on http://
www.predictcancer.org, breast cancer on http://research.nki.nl/
ibr/ and glioblastoma on http://www.eortc.be/tools/gbmcalcula-
tor/.Application
In this phase, the knowledge generated by Rapid Learning is ap-
plied with the help of decision support systems (DSS). Typically,
these are tools and software applications that can be used to applyFig. 3. Example of aknowledge-driven healthcare in practice. Examples include nomo-
grams (as in Fig. 3) [14,15,22–26] and websites such as those
named above, for radiotherapy models, which help predict the ex-
pected treatment outcome of radiotherapy when they are supplied
with the parameters speciﬁcally relevant to the clinical case.
Decision support systems are neither intended nor suited as a
replacement for the physician as a healthcare professional. They
are designed to support the physician and the patient in making
a more informed decision with respect to a particular treatment.
The use of computer models to support healthcare professionals
in their efforts is, of course, not new in radiation oncology. Phys-
ics-based computer models, with which doses can be better calcu-
lated than by hand, as well as radiobiology-based Normal Tissue
Complications Probability (NTCP) and Tumour Control Probability
(TCP) models to correlate the given dose with tumour control
and toxicity, are commonplace within radiotherapy [27,28]. For
example, geometrical models based on tumour volume alone have
shown additional value next to classical TNM classiﬁcation as well
[29]. The new models emerging from Rapid Learning are a natural
extension of this to patient outcomes. However, a key difference is
that the Rapid Learning models are more ‘holistic’ and multifacto-
rial than the current physics- or radiobiology-based models, as
they also take patient, tumour and non-radiotherapy factors into
account [30]. For instance, a Rapid Learning model of radiation-in-
duced oesophagitis shows that the risk for this toxicity not only de-
pends on the dose to which the oesophagus is exposed, but also
greatly increases if chemotherapy is given concomitantly [31]. An-
other example is that the survival of non-metastatic unresectable
non-small cell lung cancer is better predicted by a multifactorial
model based on clinical and imaging variables, and even more
when blood biomarkers are included [31,32]. In both cases the
models outperform the prognostic value of TNM classiﬁcation.Evaluation
The underlying idea in Rapid Learning is that the application of
knowledge acquired from routine data leads to predictability of
treatment outcomes, meaning that these outcomes can be im-
proved in terms of both effectiveness (achieving the desired result)
and efﬁciency (the resources needed to achieve the result). Natu-
rally, this needs to be continually evaluated, focusing on the ques-
tion ‘Is the outcome of the treatment as predicted?’ Compared to
the consensus- and evidence based guideline knowledge that is
preferably constructed with (meta analysis of) robust experimental
data that are interpreted by multiple stakeholders including health
care economists and patient representatives, the prediction modelsnomogram [22].
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ing, having high-quality data with respect to outcomes is crucial.
This implies the use of broadly accepted taxonomies such as RE-
CIST or pathological Complete Response for tumour response
[33], CTCAE for toxicity [34] and euroQoL for quality of life & util-
ities (which allow to calculate Quality Adjusted Life Year (QALY))
[35,36]. Naturally, keeping thorough records of treatment out-
comes is important not only for Rapid Learning, but also for initia-
tives such as the quality registration system for lung cancer
patients initiated by the Dutch Society for Radiotherapy and
Oncology.Fig. 4. Complementary instead of contradictory approaches.Discussion
Tailored cancer treatment is a necessity, to ensure not only that
the individual patient receives the treatment that best suits his or
her wishes, and to avoid under or overtreatment but also to opti-
mise resources, so that the right resources are being used for the
right patients in healthcare in a broader sense. However, tailored
cancer treatment is also a challenge: the great diversity of cancer
patients and treatments implies that it is by no means always clear
which choice leads to which treatment outcome. Especially in
cases where the treatment options under consideration have no
clear clinical advantage in the outcome, a shared decision-making
process can be employed in order to make the most of patient
preferences.
Tailored therapy is also necessary for radiotherapy. The radio-
sensitivity of tumours and normal tissues is often unknown, cer-
tainly not homogeneous within an individual patient, and even
less so between patients [37–40]. In addition, the range of treat-
ment options and thus the number of decisions that need to be
made within radiotherapy have risen sharply, largely due to tech-
nological innovations such as IMRT, VMAT, IGRT and particle ther-
apy as well as innovative combinations with systemic and targeted
treatments such as tyrosine inhibitors or monoclonal antibodies
(e.g., Cetuximab). Opting for a particular radiation treatment on
the basis of expected outcomes is therefore difﬁcult, and the estab-
lished guidelines and literature provide only limited support in this
regard.
This article has discussed Rapid Learning as a means of support
when deciding on a tailored radiation treatment. In essence, Rapid
Learning involves reusing local, clinical, routine data to develop
knowledge in the form of models that can predict treatment out-
comes, and then clinically applying and carefully evaluating these
models by way of Decision Support Systems. The hypothesis is that
treatment outcomes obtained in the past can be used to predict fu-
ture results.
Earlier attempts to introduce so-called ‘expert systems’ had
mixed results. The proposed Rapid Learning methodology is differ-
ent from the earlier attempts to deploy expert systems in several
ways: it makes use of larger quantities of relevant data (e.g. the
clinical patient population), as steadily more clinical data become
available electronically in the clinical environment. This also en-
ables validation in one’s local practice which is a prerequisite for
any expert system to be accepted, similar to commissioning and
acceptance of treatment planning systems in radiotherapy. In con-
trast with expert systems, Rapid Learning employs quantitative
models in addition to qualitative models. Finally, the de facto cur-
rent expert system from ‘‘literature and guidelines based on clini-
cal trials’’ has limited application to personalised medicine. This
will drive the demand for more ﬂexible and rapidly updated expert
systems such as proposed in this review.
The Rapid Learning approach seems to contradict the principles
of evidence-based medicine, in which treatment decisions are
based solely on results obtained from controlled clinical trials. Infact it does not; both approaches are complementary (Fig. 4). This
is compounded by the fact that Rapid Learning is based on results
obtained from the less controlled setting of clinical practice. These
different environments yield different insights. Controlled clinical
trials primarily aim to identify small improvements in results be-
tween two treatments in a patient group that is as homogeneous
as possible. In contrast, Rapid Learning will reveal major differ-
ences in treatment outcomes that stem from the heterogeneity of
the patient group. It will be inferior in detecting minor differences
in treatments due to the lower quality of the data recorded in clin-
ical practice as compared to the same treatment in a clinical trial.
In addition, Rapid Learning can be seen as an alternative for situa-
tions in which there are insufﬁcient evidence to make decisions in
line with the principles of evidence-based medicine. This is often
the case with technological innovations; for instance, when consid-
ering the use of new techniques (e.g., IMRT, protons) in the ﬁeld of
radiotherapy [41].
Rapid Learning is new and still needs to prove its value as a sup-
plement to traditional, evidence-based approaches. There are sev-
eral developments that might help Rapid Learning change the way
scientiﬁc evidence is viewed in medicine: (a) Technological ad-
vances will be created by larger and higher quality databases that
link electronic health records with research databases, as well as
the advent of the Semantic Web with increased interoperability
and distributed learning approaches that enable learning from data
without the need for data to leave the hospital; (b) The develop-
ment by domain experts of qualitative criteria to evaluate evidence
coming from large databases and rapid learning approaches; (c)
The increased pressure and possible reimbursement from health-
care payers to use Decision Support Systems, especially for high
cost treatments such as proton therapy; and (d) The development
of ‘‘clinical grade’’ and certiﬁed commercial decision support
systems.
Radiotherapy seems to be the ideal setting to study the value of
Rapid Learning, given the ﬁeld’s high degree of computerisation, as
well as its long use and acceptance of predictive models. Within
clinical radiotherapy, models and planning systems should become
available that make it possible to not only plan on the basis of
physical dose and Dose Volume Histograms parameters, but also
to explain the relationship with the expected clinical outcomes
in individual patients. Translating knowledge to an individual pa-
tient is challenging, particularly in so-called preference-sensitive
situations where there are trade-offs between options with more
or less equally desirable outcomes, but in which different individ-
uals may value differently e.g. in terms of side effects. As access to
health-related information improves, patients have an increased
desire to be in charge of their own life and health. Despite invest-
ment in efforts to improve the skills of clinicians, patients continue
P. Lambin et al. / Radiotherapy and Oncology 109 (2013) 159–164 163to report low levels of involvement [42]. There is indeed evidence
level 1 from a Cochrane systematic review evaluating 86 studies
involving 20,209 participants included in published randomised
controlled trials demonstrating that decision aids increase people’s
involvement, support informed values-based choices in patient-
practitioner communication, and improve knowledge and realistic
perception of outcomes. We therefore believe the next step will be
to integrate, whenever possible, Shared Decision Making ap-
proaches (see for example www.treatmentchoice.info;
www.optiongrid.org) to include the patient perspective in the
choice of best treatment [26].Conﬂict of interest
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